NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

中國的Anlotinib市場(2021年∼2025年)

Investigation Report on China's Anlotinib Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1010203
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Anlotinib市場(2021年∼2025年) Investigation Report on China's Anlotinib Market 2021-2025
出版日期: 2021年06月08日內容資訊: 英文 50 Pages
簡介

Anlotinib,是一種口服多靶向小分子酪氨酸激酶抑製劑,可靶向多種血管生成因子受體抑制腫瘤血管生成。可用於晚期非小細胞肺癌(NSCLC)、軟組織肉瘤、透明細胞肉瘤等疾病。Anlotinib由中國正大天晴藥業集團股份有限公司開發,2018年中國核可銷售。適應症是有2種以上化療的治療經歷的進行性/復發性非小細胞肺癌。在中國市場中正大天晴藥業集團股份有限公司成為唯一的製藥企業。

中國市場中Anlotinib的銷售額從2018年到2020年年年增加。2019年銷售量達6億5,000萬人民幣,與前一年同期比較增加到約20倍。Anlotinib於2018年核可,其治療上的優點受到醫院和患者的歡迎,成為銷售額增加的要素。中國市場中Anlotinib從2018年到2020年的年複合成長率記錄了444.49%。

本報告提供中國的Anlotinib市場相關調查,產品概要,新型冠狀病毒感染疾病(COVID-19)的影響,中國整體及各地區的銷售趨勢,製藥企業的市場佔有率,銷售額及銷售數,價格趨勢,市場預測,市場成長要素,市場機會,課題等彙整資料。

目錄

第1章 Anlotinib概要

  • Anlotinib的適應症
  • 中國的Anlotinib的開發
  • 中國的Anlotinib的政府核准
  • 新型冠狀病毒感染疾病(COVID-19)對銷售的影響

第2章 中國的Anlotinib的銷售趨勢(2018年∼2020年)

  • Anlotinib的銷售額
    • 銷售額:全體
    • 銷售額:各地區
  • Anlotinib的銷售數
    • 銷售數:全體
    • 銷售數:各地區
  • Anlotinib的銷售趨勢:各劑型
    • 膠囊
    • 其他劑型

第3章 中國的主要Anlotinib製造企業(2018年∼2020年)

  • 主要企業的市場佔有率
    • 銷售額
    • 銷售數
  • Jiangsu Chia Tai Tianqing Pharmaceutical Holdings Co., Ltd.
    • 企業簡介
    • Fukewei的中國國內的銷售額

第4章 中國的Anlotinib的價格(2020∼2021年)

  • Chia Tai Tianqing Pharmaceutical Holdings Co., Ltd. (Fukewei)
  • 其他企業分析

第5章 中國的Anlotinib市場預測(2021年∼2025年)

  • 市場發展的影響要素
    • 新型冠狀病毒感染疾病(COVID-19)的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2106531

Anlotinib is an oral multi-targeting small-molecule tyrosine kinase inhibitor that can target multiple angiogenic factor receptors to inhibit tumor angiogenesis. It can be used for advanced non-small cell lung cancer (NSCLC), soft tissue sarcoma, clear cell sarcoma, and other diseases. Anlotinib was developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. in China. Anlotinib was approved for marketing in China in 2018. Its indication is locally advanced or metastatic non-small cell lung cancer that has progressed or recurred after receiving at least 2 types of systemic chemotherapy in the past. By 2020, Anlotinib has been approved for 3 indications in China, and the only manufacturer is Chia Tai Tianqing Pharmaceutical Group Co., Ltd. in the Chinese market.

According to CRI's market research, the sales value of Anlotinib in the Chinese market increases year by year from 2018 to 2020. Especially in 2019, sales reached CNY 650 million, an increase of about 20 times year on year. The main reason is that Anlotinib has been welcomed by hospitals and patients based on its therapeutic advantages since its approval in 2018. The CAGR of the sales value of Anlotinib in the Chinese market is 444.49% from 2018 to 2020.

CRI predicts that the sales of Rotinib in the Chinese market will continue to grow from 2021 to 2025, with the increase in the number of cancer patients. Lung cancer is the leading cause of human cancer deaths, accounting for about one-fifth of all cancer deaths. According to the data on the number of new cancers in 2020 released by WHO, the number of new lung cancers and deaths in China in 2020 is 280,000 and 710,000, respectively, which are the highest in the world. Anlotinib-treated non-small cell lung cancer (NSCLC) accounts for 80% to 90% of lung cancer in China. The huge patient population will continue to expand the market of Anlotinib. In addition, the increase in indications will also increase sales. In the first half of 2021, Focavi's fourth indication is in the state of approval in China. It is expected that with the approval of new indications in the future, the patient population of Anlotinib will expand, and sales value and sales volume will also increase to a certain extent.

Topics Covered:

  • The impact of COVID-19 on China's Anlotinib market
  • Sales value of China's Anlotinib 2016-2020
  • Competitive landscape of China's Anlotinib market
  • Prices of Anlotinib in China
  • Prices of Anlotinib in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Anlotinib market
  • Prospect of China's Anlotinib market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Anlotinib

  • 1.1 Indications for Anlotinib
  • 1.2 Development of Anlotinib in China
  • 1.3 Governmental Approval of Anlotinib in China
  • 1.4 The Impact of COVID-19 on Anlotinib sales in China

2 Sales of Anlotinib in China, 2018-2020

  • 2.1 Sales Value of Anlotinib
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Anlotinib
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Anlotinib by Dosage Form in China, 2018-2020
    • 2.3.1 Capsules
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Anlotinib Manufacturers in China, 2018-2020

  • 3.1 Analysis of Market Share of Major Anlotinib Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Jiangsu Chia Tai Tianqing Pharmaceutical Holdings Co., Ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Fukewei (Jiangsu Chia Tai Tianqing Pharmaceutical Holdings Co., Ltd.'s Anlotinib) in China

4 Prices of Anlotinib for Different Manufacturers in China, 2020-2021

  • 4.1 Chia Tai Tianqing Pharmaceutical Holdings Co., Ltd. (Fukewei)
  • 4.2 Analysis of Other Enterprises

5 Prospect of Chinese Anlotinib drug Market, 2021-2025

  • 5.1 Influential Factors of Chinese Anlotinib Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Anlotinib Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Anlotinib Capsules Registration in China
  • Chart Sales Value of Anlotinib Capsules over the World
  • Chart Sales Value of Anlotinib Capsules in China, 2018-2020
  • Chart Sales Value of Anlotinib Capsules in China by Region, 2018-2020
  • Chart Sales Volume of Anlotinib Capsules in China, 2018-2020
  • Chart Sales Volume of Anlotinib Capsules in China by Region, 2018-2020
  • Chart Market Share by Sales Value of Top Anlotinib Manufacturers in China, 2018-2020
  • Chart Sales Value and Volume of Fukewei in China, 2018-2020
  • Chart Referential Prices of Fukewei in China, 2020-2021
  • Chart Forecast on Sales Value of Anlotinib in China, 2021-2025
  • Chart Forecast on Sales Volume of Anlotinib in China, 2021-2025